

=> s ((cisplatin or cis platin) (p) (taxol or paclitaxel) (p) vincristine)

1316 CISPLATIN
33809 CIS
277 PLATIN
211 CIS PLATIN
(CIS(W)PLATIN)
746 TAXOL
138 PACLITAXEL
1340 VINCRISTINE

L1 89 ((CISPLATIN OR CIS PLATIN) (P) (TAXOL OR PACLITAXEL) (P) V
NCR IISTINE)

=> s apoptosis

L2 810 APOPTOSIS

=> s l1 (p) l2

L3 6 L1 (P) L2

=> d 1-6 bib rel kwic

US PAT NO: 5,840,673 [IMAGE AVAILABLE] L3: 1 of 6
DATE ISSUED: Nov. 24, 1998
TITLE: Insulin-like growth factor binding protein 3 (IGF-BP3) in
treatment of p53-related tumors
INVENTOR: Leonard R. Buckbinder, Doylestown, PA
Nikolai Kley, Princeton Junction, NJ
Bernd R. Seizinger, Stockton, NJ
ASSIGNEE: Bristol-Myers Squibb Company, Princeton, NJ (U.S. corp.)
APPL-NO: 08/713,052
DATE FILED: Sep. 12, 1996
ART-UNIT: 166
PRIM-EXMR: Sally P. Teng
LEGAL-REP: Timothy J. Gaul

US PAT NO: 5,840,673 [IMAGE AVAILABLE] L3: 1 of 6

DETDSC:

DETD(10)

In addition, since IGF-I plays a role in "apoptosis", inhibition of
the IGF-I-IGF-IR axis could sensitize tumor cells to conventional
cytotoxic agents or radiation and provide a novel therapeutic. . .
co-administer a cytotoxic agent or other anti-cancer agent as an
additional step in the foregoing methods. Suitable cytotoxic agents
include "paclitaxel", "cisplatin", etoposide, paraplantin, bleomycin,
plicamycin, doxorubicin, dimethyl triazeno imidazole carboxamide (DTIC),
daunorubicin, cytarabine, procarbazine, 1-(.beta.-chloroethyl)-1-
nitrosourea (CCNU), hydroxyurea, melphalan, 1,3-bis (.beta.-chloroethyl)-
1-nitrosourea (BCNU), "vincristine", vinblastine, o,p'-dichloro-
diphenyldichloroethane (o,p'-DDD) (mitotane), cyclophosphamide,
ifosfamide (a cyclophosphamide derivative), 5-fluorouracil, busulfan,
dactinomycin, mitomycin-C, 6-thioguanine, thio-TEPA, chloroambucil,
6-mercaptopurine, methotrexate, nitrogen mustard, . . .

US PAT NO: 5,831,066 [IMAGE AVAILABLE] L3: 2 of 6
DATE ISSUED: Nov. 3, 1998
TITLE: Regulation of bcl-2 gene expression
INVENTOR: John C. Reed, Carlsbad, CA
ASSIGNEE: The Trustees of the University of Pennsylvania,
Philadelphia, PA (U.S. corp.)
APPL-NO: 08/465,485
DATE FILED: Jun. 5, 1995
ART-UNIT: 169
PRIM-EXMR: David T. Fox
ASST-EXMR: Amy J. Nelson
LEGAL-REP: Oblon, Spivak, McClelland, Maier & Neustadt, P.C.

US PAT NO: 5,831,066 [IMAGE AVAILABLE] L3: 2 of 6
REL-US-DATA: Continuation of Ser. No. 124,256, Sep. 20, 1993,
abandoned, which is a continuation-in-part of Ser. No.
840,716, Feb. 21, 1992, abandoned, which is a
continuation-in-part of Ser. No. 288,692, Dec. 22, 1988,
abandoned.

DETDSC:

DETD(144)

High . . . lymphoid cells to killing induced by a wide variety of

cancer chemotherapeutic agents including, but not limited to, Ara-C, MTX,
"vincristine", "taxol", "cisplatin", adriamycin, etoposide,
mitozantrone, 2-chlorodeoxyadenosine, dexamethasone (DEX), and alkylating
agents. (Miyashita, T. and Reed, J. C., Cancer Res. 52:5407, Oct. 1, . . .
that all have in common the ability to ultimately trigger cancer cell
death by activating endogenous cellular pathways leading to "apoptosis"
(Eastman, A. Cancer Cells 2:275 (1990)). It is understood that the
claimed anticode molecules and analogs thereof as used herein. . .

US PAT NO: 5,686,595 [IMAGE AVAILABLE] L3: 3 of 6
DATE ISSUED: Nov. 11, 1997
TITLE: Bcl-2-associated proteins
INVENTOR: John C. Reed, Carlsbad, CA
Shinichi Takayama, San Diego, CA
Takaaki Sato, San Diego, CA
ASSIGNEE: La Jolla Cancer Research Foundation, La Jolla, CA (U.S.
corp.)
APPL-NO: 08/461,359
DATE FILED: Jun. 5, 1995
ART-UNIT: 184
PRIM-EXMR: Suzanne E. Ziska

US PAT NO: 5,686,595 [IMAGE AVAILABLE] L3: 3 of 6
REL-US-DATA: Division of Ser. No. 152,405, Nov. 12, 1993, Pat. No.
5,539,094.

DETDSC:

DETD(40)

Expression . . . in insect cells and Sindbis virus in mammalian
cells; and 6) various chemotherapeutic drugs that act by different
mechanisms, including "vincristine" and "taxol", which inhibit
microtubule formation, cytosine arabinoside, which is an antimetabolite,
methotrexate, which is an inhibitor of nucleotide synthesis, etoposide
and . . . adriamycin and daunomycin, which intercalate into DNA,
cyclophosphamide congeners, which are alkylating agents, and BCNU (a
nitrogen mustard), 2-chlorodeoxyadenosine and "cisplatin". Thus,
expression of a BAP in a cell using the methods described above can
reduce the level of free Bcl-2 in a cell and modulate the susceptibility
of a cell to "apoptosis" induced by these or other chemical or physical
agents.

US PAT NO: 5,650,491 [IMAGE AVAILABLE] L3: 4 of 6
DATE ISSUED: Jul. 22, 1997
TITLE: BCL-2-associated proteins
INVENTOR: John C. Reed, Carlsbad, CA
Shinichi Takayama, San Diego, CA
Takaaki Sato, San Diego, CA
ASSIGNEE: La Jolla Cancer Research Foundation, La Jolla, CA (U.S.
corp.)
APPL-NO: 08/461,360
DATE FILED: Jun. 5, 1995
ART-UNIT: 184
PRIM-EXMR: Robert A. Wax
ASST-EXMR: G. E. Bugaisky
LEGAL-REP: Campbell & Flores LLP

US PAT NO: 5,650,491 [IMAGE AVAILABLE] L3: 4 of 6
REL-US-DATA: Division of Ser. No. 152,485, Nov. 12, 1993, Pat. No.
5,539,094, Jul. 23, 1996.

DETDSC:

DETD(40)

Expression . . . in insect cells and Sindbis virus in mammalian
cells; and 6) various chemotherapeutic drugs that act by different
mechanisms, including "vincristine" and "taxol", which inhibit
microtubule formation, cytosine arabinoside, which is an antimetabolite,
methotrexate, which is an inhibitor of nucleotide synthesis, etoposide
and . . . adriamycin and daunomycin, which intercalate into DNA,
cyclophosphamide congeners, which are alkylating agents, and BCNU (a
nitrogen mustard), 2-chlorodeoxyadenosine and "cisplatin". Thus,
expression of a BAP in a cell using the methods described above can
reduce the level of free Bcl-2 in a cell and modulate the susceptibility
of a cell to "apoptosis" induced by these or other chemical or physical
agents.

US PAT NO: 5,641,866 [IMAGE AVAILABLE] L3: 5 of 6
DATE ISSUED: Jun. 24, 1997
TITLE: Bcl-2-associated proteins
INVENTOR: John C. Reed, Carlsbad, CA
Shinichi Takayama, San Diego, CA
Takaaki Sato, San Diego, CA
ASSIGNEE: La Jolla Cancer Research Foundation, La Jolla, CA (U.S.
corp.)

APPL-NO: 08/463,089
DATE FILED: Jun. 5, 1995
ART-UNIT: 186
PRIM-EXMR: Marian C. Knobe
ASST-EXMR: Yvonne Eyler
LEGAL-REP: Campbell & Flores

US PAT NO: 5,641,866 [IMAGE AVAILABLE] L3: 5 of 6
REL-US-DATA: Division of Ser. No. 152,485, Nov. 11, 1993, Pat. No.
5,539,094.

DETDDESC:

DETD(40)

Expression . . . in insect cells and Sindbis virus in mammalian cells; and 6) various chemotherapeutic drugs that act by different mechanisms, including **"vincristine"** and **"taxol"**, which inhibit microtubule formation, cytosine arabinoside, which is an antimetabolite, methotrexate, which is an inhibitor of nucleotide synthesis, etoposide and . . . adriamycin and daunomycin, which intercalate into DNA, cyclophosphamide congeners, which are alkylating agents, and BCNU (a nitrogen mustard), 2-chlorodeoxyadenosine and **"cisplatin"**. Thus, expression of a BAP in a cell using the methods described above can reduce the level of free Bcl-2 in a cell and modulate the susceptibility of a cell to **"apoptosis"** induced by these or other chemical or physical agents.

US PAT NO: 5,539,094 [IMAGE AVAILABLE] L3: 6 of 6
DATE ISSUED: Jul. 23, 1996
TITLE: DNA encoding Bcl-2-associated proteins
INVENTOR: John C. Reed, Carlsbad, CA
Shinichi Takayama, San Diego, CA
Takaaki Sato, San Diego, CA
ASSIGNEE: La Jolla Cancer Research Foundation, La Jolla, CA (U.S.
corp.)

APPL-NO: 08/152,485
DATE FILED: Nov. 12, 1993
ART-UNIT: 182
PRIM-EXMR: Garnette D. Draper
ASST-EXMR: Shelly Guest Cermak
LEGAL-REP: Campbell and Flores

US PAT NO: 5,539,094 [IMAGE AVAILABLE] L3: 6 of 6

DETDDESC:

DETD(40)

Expression . . . in insect cells and Sindbis virus in mammalian cells; and 6) various chemotherapeutic drugs that act by different mechanisms, including **"vincristine"** and **"taxol"**, which inhibit microtubule formation, cytosine arabinoside, which is an antimetabolite, methotrexate, which is an inhibitor of nucleotide synthesis, etoposide and . . . adriamycin and daunomycin, which intercalate into DNA, cyclophosphamide congeners, which are alkylating agents, and BCNU (a nitrogen mustard), 2-chlorodeoxyadenosine and **"cisplatin"**. Thus, expression of a BAP in a cell using the methods described above can reduce the level of free Bcl-2 in a cell and modulate the susceptibility of a cell to **"apoptosis"** induced by these or other chemical or physical agents.